Insider Trading Alert - BIIB, JAZZ And KWK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, April 21, 2014, 37 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $415.74 to $3,850,000.00.

Highlighted Stocks Traded by Insiders:

Biogen Idec (BIIB) - FREE Research Report

Holtzman Steven H, who is EVP Corporate Development at Biogen Idec, sold 1,221 shares at $291.00 on April 21, 2014. Following this transaction, the EVP Corporate Development owned 6,970 shares meaning that the stake was reduced by 14.91% with the 1,221-share transaction.

The shares most recently traded at $302.48, up $11.48, or 3.8% since the insider transaction. Historical insider transactions for Biogen Idec go as follows:

  • 4-Week # shares sold: 5,123
  • 12-Week # shares sold: 60,980
  • 24-Week # shares sold: 78,439

The average volume for Biogen Idec has been 1.8 million shares per day over the past 30 days. Biogen Idec has a market cap of $68.7 billion and is part of the health care sector and drugs industry. Shares are up 6.58% year-to-date as of the close of trading on Monday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 45.1. Currently, there are 13 analysts who rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Winningham Rick E, who is Director at Jazz Pharmaceuticals, sold 27,500 shares at $140.00 on April 21, 2014. Following this transaction, the Director owned 13,587 shares meaning that the stake was reduced by 66.93% with the 27,500-share transaction.

The shares most recently traded at $146.63, up $6.63, or 4.52% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 5,750
  • 12-Week # shares sold: 558,638
  • 24-Week # shares sold: 566,638

The average volume for Jazz Pharmaceuticals has been 1.3 million shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $7.9 billion and is part of the health care sector and drugs industry. Shares are up 9.3% year-to-date as of the close of trading on Monday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 43.9. Currently, there are 8 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Quicksilver Resources (KWK) - FREE Research Report

Darden Thomas F, who is Director at Quicksilver Resources, sold 5,000 shares at $3.00 on April 21, 2014. Following this transaction, the Director owned 5.6 million shares meaning that the stake was reduced by 0.09% with the 5,000-share transaction.

The shares most recently traded at $3.06, up $0.06, or 1.96% since the insider transaction. Historical insider transactions for Quicksilver Resources go as follows:

  • 4-Week # shares sold: 15,000
  • 12-Week # shares sold: 30,000
  • 24-Week # shares sold: 50,000

The average volume for Quicksilver Resources has been 3.5 million shares per day over the past 30 days. Quicksilver Resources has a market cap of $540.4 million and is part of the basic materials sector and energy industry. Shares are up 2.61% year-to-date as of the close of trading on Monday.

Quicksilver Resources Inc., an independent oil and gas company, is engaged in the acquisition, exploration, development, production, and sale of natural gas, natural gas liquids, and oil in North America. The company has a P/E ratio of 2.7. Currently, there are 2 analysts who rate Quicksilver Resources a buy, 3 analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KWK - FREE

TheStreet Quant Ratings rates Quicksilver Resources as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow. Get the full Quicksilver Resources Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers